Original Data
Rev Diabet Stud,
2004,
1(2):80-88 |
DOI 10.1900/RDS.2004.1.80 |
Polyclonal Anti-T-Cell Therapy for Type 1 Diabetes Mellitus of Recent Onset
Frantisek Saudek, Tereza Havrdova, Petr Boucek, Ludmila Karasova, Peter Novota, Jelena Skibova
Diabetes Center, Institute for Clinical and Experimental Medicine, Videnska 1958/9, 14021 Prague 4, Czech Republic.
Address correspondence to: Frantisek Saudek, e-mail: frantisek.saudek@medicon.cz
Keywords: Type 1 diabetes, immune intervention, antithymocyte globulin, ATG, insulin, C-peptide
Abstract
The destruction of pancreatic β-cells in type 1 diabetes mellitus is mediated by autoreactive T-lymphocyte clones. We initiated a prospective randomized controlled trial of polyclonal rabbit anti-T-cell globulin (ATG) in patients with type 1 diabetes within 4 weeks of diagnosis and with residual post-glucagon C-peptide levels still over 0.3 nmol/l. ATG was administered as an initial bolus of 9 mg/kg followed by 3 consecutive doses of 3 mg/kg. An interim analysis was performed to establish whether any significant changes in C-peptide production and insulin requirement had occurred that would justify the continuation of this pilot study. By May 2004, 11 subjects were assigned to treatment with ATG along with intensified insulin therapy and 6 to intensified insulin therapy with placebo, and were followed for a period of at least 6 months. During the first 12 months a significant difference in the insulin dose trends was found between the groups (p = 0.010) with a lower insulin dosage in the ATG group. There was also a difference in the glucagon stimulated C-peptide level trends of marginal significance (p = 0.068). Compared to values at screening, stimulated C-peptide levels significantly improved in the ATG group (p = 0.012) but not in the placebo group. Complete diabetes remission occurred in 2 patients in the ATG and in none of the placebo group. Glycosylated hemoglobin at 12 months tended to be lower in the ATG group (p = 0.088). Significant adverse effects of ATG treatment, mainly transient fever and moderate symptoms of serum sickness (7 and 6 subjects, respectively) were observed during the first month only. The interim analysis of this ongoing study suggests that short-term ATG therapy in type 1 diabetes of recent onset contributes to the preservation of residual C-peptide production and to lower insulin requirements in the first year following diagnosis.
Fulltext:
HTML
, PDF
(358KB)
This article has been cited by other articles:
|
Immune-Directed Therapy for Type 1 Diabetes at the Clinical Level: The Immune Tolerance Network (ITN) Experience
Ehlers MR, Nepom GT
Rev Diabet Stud 2012. 9(4):359-371
|
|
|
Regulatory T-cells in Graves' orbitopathy: baseline findings and immunomodulation by anti-T lymphocyte globulin
Kahaly GJ, Shimony O, Gellman YN, Lytton SD, Eshkar-Sebban L, Rosenblum N, Refaeli E, Kassem S, Ilany J, Naor D
J Clin Endocrinol Metab 2011. 96(2):422-429
|
|
|
The potential utility of bone marrow or umbilical cord blood transplantation for the treatment of type I diabetes mellitus
Mabed M
Biol Blood Marrow Transplant 2011. 17(4):455-464
|
|
|
Stem cell-based therapies and immunomodulatory approaches in newly diagnosed type 1 diabetes
Couri CE, Voltarelli JC
Curr Stem Cell Res Ther 2011. 6(1):10-15
|
|
|
Immunotherapy of type 1 diabetes - how to rationally prioritize combination therapies in T1D
Boettler T, von Herrath M
Int Immunopharmacol 2010. 10(12):1491-1495
|
|
|
Efforts to prevent and halt autoimmune beta cell destruction
Haller MJ, Atkinson MA, Schatz DA
Endocrinol Metab Clin North Am 2010. 39(3):527-539
|
|
|
Immunotherapy of type 1 diabetes: where are we and where should we be going?
Luo X, Herold KC, Miller SD
Immunity 2010. 32(4):488-499
|
|
|
Stem cell therapy for type 1 diabetes mellitus
Aguayo-Mazzucato C, Bonner-Weir S
Nat Rev Endocrinol 2010. 6(3):139-148
|
|
|
Autologous hematopoietic stem cell transplantation for childhood autoimmune disease
Milanetti F, Abinun M, Voltarelli JC, Burt RK
Pediatr Clin North Am 2010. 57(1):239-271
|
|
|
Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice
Parker MJ, Xue S, Alexander JJ, Wasserfall CH, Campbell-Thompson ML, Battaglia M, Gregori S, Mathews CE, Song S, Troutt M, Eisenbeis S, Williams J, Schatz DA, Haller MJ, Atkinson MA
Diabetes 2009. 58(10):2277-2284
|
|
|
Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future
Rewers M, Gottlieb P
Diabetes Care 2009. 32(10):1769-1782
|
|
|
C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus
Couri CE, Oliveira MC, Stracieri AB, Moraes DA, Pieroni F, Barros GM, Madeira MI, Malmegrim KC, Foss-Freitas MC, Simões BP, Martinez EZ, Foss MC, Burt RK, Voltarelli JC
JAMA 2009. 301(15):1573-1579
|
|
|
Diabetes - adult stem cells as a future alternative therapy?
Ulicna M, Danisovic L, Danihel L, Vojtassak J
Bratisl Lek Listy 2009. 110(12):773-776
|
|
|
Engineered antibodies for type 1 diabetes
Hampe CS
Curr Opin Investig Drugs 2009. 10(4):336-345
|
|
|
Stem cell therapy for type 1 diabetes mellitus: a review of recent clinical trials
Couri CE, Voltarelli JC
Diabetol Metab Syndr 2009. 1(1):19
|
|
|
An update on preventive and regenerative therapies in diabetes mellitus
Reimann M, Bonifacio E, Solimena M, Schwarz PE, Ludwig B, Hanefeld M, Bornstein SR
Pharmacol Ther 2009. 121(3):317-331
|
|
|
Harnessing regulatory T cells for the therapy of lupus and other autoimmune diseases
Sharabi A, Mozes E
Immunother 2009. 1(3):385-401
|
|
|
Autologous stem cell transplantation for early type 1 diabetes mellitus
Couri CE, Voltarelli JC
Autoimmunity 2008. 41(8):666-672
|
|
|
Human regulatory T cells: role in autoimmune disease and therapeutic opportunities
Brusko TM, Putnam AL, Bluestone JA
Immunol Rev 2008. 223:371-390
|
|
|
Imaging the Beta-Cell Mass: Why and How
Saudek F, Brogren CH, Manohar S
Rev Diabet Stud 2008. 5(1):6-12
|
|
|
Beta-cell regeneration to treat Type 1 diabetes mellitus
Barra Couri CE, Foss-Freitas MC, Foss MC, Voltarelli JC
Expert Rev Endocr Metabol 2008. 3(1):51-60
|
|
|
Treatment of autoimmune disease with rabbit anti-T lymphocyte globulin: clinical efficacy and potential mechanisms of action
Lytton SD, Denton CP, Nutzenberger AM
Ann N Y Acad Sci 2007. 1110:285-296
|
|
|
Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus
Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, Coutinho M, Malmegrim KC, Foss-Freitas MC, Simoes BP, Foss MC, Squiers E, Burt RK
JAMA 2007. 297(14):1568-1576
|
|
|